

AMOEBBA COMMUNICATES ABOUT EUROPEAN WORKING GROUP HELD ON ITS REGULATORY DOSSIER

Lyon (France), September 11th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating bacterial risk in water and wound care applications, communicates today that the Working Group on Microorganisms met on September 8th, 2017 at the European Chemicals Agency (ECHA) headquarters in Helsinki.

AMOEBBA, represented by Fabrice PLASSON (Chief Executive Officer) and accompanied by an expert on amoeba-microorganisms' interactions, took part in this meeting. During this 6-hour session, AMOEBA had the complete and entire opportunity to share its views on all points of the dossier.

This Working Group meeting, forming part of the regulatory dossier peer review by the Member States, represents a major step in the evaluation of the BIOMEBA biocidal product active substance, *Willaertia magna C2c Maky*.

The Working Group has confirmed its willingness to close the evaluation of the active substance during the December 2017 ECHA Biocidal Products Committee session.

"This newly created expert Working Group, that met for the very first time, allowed us to intensively and pragmatically share our views on each technical and scientific aspect of our biological technology."
stated Fabrice PLASSON, Chief Executive Officer of AMOEBA.



About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾ AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn⁽²⁾. Similarly, in a global wound care market estimated at EUR 15.2bn⁽³⁾, AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million⁽⁴⁾. The use of Willaertia magna C2c Maky in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on www.amoeba-biocide.com.

(1): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

(3) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(4) BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

Contacts:

Amoéba

Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr